title: Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality.
abstract: The influence of infarct location on arterial patency, left ventricular function and mortality after 150 mg of intravenous recombinant tissue-type plasminogen activator (rt-PA) and selective coronary angioplasty was studied in 386 patients with acute myocardial infarction. In 329 patients with acute and 1 week angiograms, the 90 min infarct-related artery patency rate after rt-PA in the left anterior descending, the left circumflex and the right coronary artery was 77, 68 and 68%, respectively. Angioplasty, performed in half the patients, resulted in a final acute patency rate of 93%, which was not related to arterial distribution. Repeat catheterization and revascularization were required in 12% of patients before day 7 and were independent of arterial distribution. The reocclusion rate for the right coronary artery (21%) was higher than that for the left anterior descending (12%) or left circumflex (5%) artery (p = 0.01). Acute and 1 week contrast ventriculograms suitable for analysis were available in 266 patients. Whereas serial left ventricular ejection fraction did not improve during the course of this study, serial regional wall motion (centerline chord method) improved in each arterial distribution. The in-hospital mortality rate of 6% was not related to arterial distribution, although death was twice as likely with proximal compared with distal lesions. Ten of 11 patients who died in the group with the left anterior descending artery as the infarct-related artery had a lesion proximal to the first septal perforator branch.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, University of Michigan, Ann Arbor.
authors.forename: E R
authors.initials: ER
authors.lastname: Bates
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: R S
authors.initials: RS
authors.lastname: Stack
authors.forename: L
authors.initials: L
authors.lastname: Aronson
authors.forename: B S
authors.initials: BS
authors.lastname: George
authors.forename: R J
authors.initials: RJ
authors.lastname: Candela
authors.forename: D J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: C W
authors.initials: CW
authors.lastname: Abbottsmith
authors.forename: L
authors.initials: L
authors.lastname: Anderson
authors.forename: B
authors.initials: B
authors.lastname: Pitt
mesh_terms: D000368:Aged; D000800:Angioplasty, Balloon; D002986:Clinical Trials as Topic; D003331:Coronary Vessels / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006321:Heart / Q000503:physiopathology; D006331:Heart Diseases / Q000209:etiology; D006352:Heart Ventricles; D006801:Humans; D009026:Mortality; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D009206:Myocardium / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator